Is ondansetron (Zofran) safe for use during pregnancy, and when should it be prescribed?

Ondansetron (Zofran) in Pregnancy

Ondansetron is safe and effective for treating nausea and vomiting in pregnancy and should be used as a second-line antiemetic when first-line agents (antihistamines, phenothiazines, or doxylamine/pyridoxine) fail to control symptoms. 1

Treatment Algorithm

First-Line Therapy

Start with these agents initially for nausea and vomiting of pregnancy (NVP) or hyperemesis gravidarum (HG):

• H1 antihistamines (promethazine, cyclizine, cinnarizine)
• Phenothiazines (prochlorperazine, chlorpromazine)
• Doxylamine/pyridoxine (Xonvea®)

These have the strongest safety data with no increased risk of congenital malformations or adverse pregnancy outcomes 1.

Second-Line Therapy: Ondansetron

Use ondansetron when first-line antiemetics are ineffective. Its use should not be discouraged 1.

Safety Profile

Overall Malformation Risk

The most comprehensive evidence from over 97,000 first-trimester exposures shows no overall increase in congenital malformations 1. A large multinational cohort study of 456,963 pregnancies found no association with fetal death, spontaneous abortion, stillbirth, or major congenital malformations (adjusted OR 1.06,95% CI 0.91-1.22) 2.

Specific Risk: Orofacial Clefting

There is a very small absolute risk increase for orofacial clefting:

• Background risk: 11 cases per 10,000 births
• With ondansetron: 14 cases per 10,000 births
• Absolute risk increase: 3 additional cases per 10,000 exposures 1

This minimal risk must be balanced against the significant morbidity of poorly managed hyperemesis gravidarum, which can lead to dehydration, electrolyte imbalances, weight loss, and nutritional deficiencies that pose real threats to both maternal and fetal health 1.

Cardiac Defects: Conflicting Evidence

Some studies suggest a possible association with cardiac septal defects, but the evidence is inconsistent:

• One Swedish study found increased risk for cardiac septum defects (RR 2.05,95% CI 1.19-3.28) 3
• A US study showed dose-dependent VSD risk (adjusted RR 3.2 for highest doses) 4
• However, the largest multinational study found no association 2
• Another large case-control study found no increased risk for most defects 5

The UK Teratology Information Service systematic review concluded that current data do not provide evidence that ondansetron increases overall malformation rates 1.

Clinical Counseling Points

Reassure patients that:

1. Ondansetron is considered safe based on extensive human data
2. The absolute risk increase for any specific defect is very small
3. The risks of untreated severe NVP/HG (dehydration, malnutrition, Wernicke's encephalopathy) are substantial and well-documented
4. The FDA classifies ondansetron as Pregnancy Category B (animal studies show no harm; adequate human studies lacking) 6

Important Caveats

Regulatory Context

• The European Medicines Authority issued warnings about first-trimester use
• The UK Medicines and Healthcare products Regulatory Agency (MHRA) did NOT issue such a warning 1
• The 2024 BJOG guideline explicitly states ondansetron use "should not be discouraged" 1

Dosing Considerations

• Most common oral daily doses: 8-12 mg/day (74.6% of prescriptions) 7
• Higher cumulative doses may carry increased risk 4
• Use the lowest effective dose

Combination Therapy

If single-agent therapy fails, use combinations of different antiemetic classes 1. Consider adding metoclopramide (also second-line due to extrapyramidal side effects) 1.

Critical Adjunct: Thiamine

Always provide thiamine supplementation (oral 100 mg three times daily or IV Pabrinex®) to all women with severe vomiting or reduced dietary intake before administering dextrose or parenteral nutrition to prevent Wernicke's encephalopathy 1.

When to Use Ondansetron

Use ondansetron when:

• First-line antiemetics have failed to adequately control symptoms
• The patient has previously responded well to ondansetron
• Severe symptoms threaten maternal nutritional status or hydration
• Quality of life is significantly impaired despite first-line therapy

The benefits of controlling severe NVP/HG substantially outweigh the minimal absolute risk increase in orofacial clefting, particularly given the well-established morbidity of untreated hyperemesis gravidarum 1.